Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.

by Chunxiang Zhang, Hongmei Zhang, Jinning Shi, Dong Wang, Xiuwei Zhang, Jian Yang, Qizhi Zhai, Aixia Ma
Published 2016-01-01